litronesib
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT01214629)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 2
Mechanism of action
- Kinesin-like protein 1INHIBITOR
KIF11 inhibitor
Allosteric inhibitor of Eg5. ALso inhibits Eg5 localization to the mitotic spindle,
Chemistry & pharmacology
Loading structure…
SMILES
CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C- Mol. weight
- 511.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105661 ↗
Also known as
- kf89617
- kf89617
- litronesib
- litronesib
- litronesib
- litronesib
- ly2523355
- ly2523355
- ly2523355
- ly-2523355
- ly-2523355
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01416389 | Phase 2 | Aug 1, 2011 | Eli Lilly |
| NCT01358019 | Phase 1 | May 1, 2011 | Kyowa Hakko Kirin |
| NCT01059643 | Phase 2 | Apr 1, 2011 | Eli Lilly |
| NCT01025284 | Phase 2 | Dec 1, 2009 | Eli Lilly |
| NCT01214655 | Phase 1 | Jun 1, 2008 | Eli Lilly |
| NCT01214642 | Phase 1 | May 1, 2008 | Eli Lilly |
| NCT01214629 | Phase 1 | Jul 1, 2007 | Eli Lilly |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 6 | 2 | 2007 |
| Kyowa Hakko Kirin | For profit | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1